Isoproterenol inhibits resistin gene expression through a GS-protein-coupled pathway in 3T3-L1 adipocytes  by Fasshauer, Mathias et al.
Isoproterenol inhibits resistin gene expression through a
GS-protein-coupled pathway in 3T3-L1 adipocytes
Mathias Fasshauera, Johannes Kleinb, Susanne Neumanna, Markus Eszlingera, Ralf Paschkea;*
aUniversity of Leipzig, Department of Internal Medicine III, Ph.-Rosenthal-Str. 27, 04103 Leipzig, Germany
bMedical University of Lu«beck, Department of Internal Medicine I, 23538 Lu«beck, Germany
Received 29 May 2001; accepted 5 June 2001
First published online 14 June 2001
Edited by Jacques Hanoune
Abstract Resistin was recently identified as a hormone secreted
by adipocytes which leads to insulin resistance in vivo and in vitro
and might therefore be an important link between obesity and
diabetes. To clarify the regulation of resistin gene expression,
3T3-L1 adipocytes were treated with various agents known to
modulate insulin sensitivity, and resistin mRNA was measured by
quantitative real-time reverse transcription-polymerase chain
reaction. Interestingly, isoproterenol treatment reduced the level
of resistin mRNA to 20% of non-treated control cells. This effect
was dose-dependent with significant inhibition occurring at
concentrations as low as 10 nM isoproterenol. Moreover,
pretreatment of adipocytes with the L-adrenergic antagonist
propranolol almost completely reversed the inhibitory effect of
isoproterenol, whereas addition of the K-adrenergic antagonist
phentolamine did not have any effect. Furthermore, the effect of
isoproterenol could be mimicked by activation of GS-proteins and
adenylyl cyclase. Thus, both cholera toxin and forskolin
decreased resistin mRNA expression in a dose-dependent fashion
by up to 90% of control levels. Taken together, these results
suggest that resistin gene expression is regulated by a protein
kinase A-dependent pathway in 3T3-L1 adipocytes. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Type 2 diabetes is among the most common chronic dis-
eases, a¡ecting about 150 million people worldwide [1]. Type
2 diabetes is characterized by insulin resistance of peripheral
tissues such as liver, muscle and fat which cannot be overcome
by hypersecretion of pancreatic L-cells [2]. Insulin resistance is
often associated with obesity [3]. The connection between in-
creased adiposity and insulin resistance is still not completely
clear. It has been shown that adipocytes secrete several factors
such as free fatty acids (FFA), tumor necrosis factor K and
angiotensinogen which cause insulin resistance in vivo and in
vitro [4]. Most recently, Steppan et al. [5,6] reported the iso-
lation of a novel adipocyte-derived signaling molecule which
they named resistin. It was shown that resistin levels are sig-
ni¢cantly increased in both genetic and diet-induced obesity in
vivo [5]. Furthermore, resistin administration caused impaired
glucose tolerance, whereas immunoneutralization of this pro-
tein improved insulin action [5]. Most interestingly, the au-
thors showed that resistin is downregulated by thiazolidine-
diones (TZDs) [5]. TZDs are a new class of anti-diabetic drugs
which enhance insulin sensitivity [5]. Therefore, resistin might
be both a link between obesity and diabetes and a candidate
to explain the anti-diabetic e¡ects of TZDs.
However, little is known concerning the control of resistin
gene expression. Steppan et al. [5] demonstrated that resistin
mRNA and protein are downregulated during fasting and
upregulated upon refeeding. Furthermore, Kim et al. [7]
showed a strong upregulation of resistin mRNA after strep-
tozotocin-diabetic mice were treated with insulin. Apart from
insulin, several other hormones such as catecholamines, glu-
cocorticoids and thyroid hormones in£uence fat cell metabo-
lism, as well as insulin sensitivity, and therefore, are potential
regulators of resistin gene expression.
Therefore, we examined the e¡ect of isoproterenol, dexa-
methasone and triiodothyronine (T3) in vitro on the expres-
sion of resistin mRNA in 3T3-L1 adipocytes. We show that
isoproterenol inhibits resistin gene expression. Furthermore,
we demonstrate that this inhibitory e¡ect is mediated via a
GS-protein-coupled pathway.
2. Materials and methods
2.1. Materials
Isoproterenol, propranolol, phentolamine, cholera toxin, forskolin,
T3, and dexamethasone were obtained from Sigma Chemical Co. (St.
Louis, MO, USA). Oligonucleotides were from MWG-Biotech (Ebers-
berg, Germany). Fetal bovine serum and cell culture reagents were
purchased from Life Technologies (Grand Island, NY, USA).
2.2. Cell culture and di¡erentiation
3T3-L1 adipocytes (American Type Culture Collection, Rockville,
MD, USA) were grown at 37‡C in 5% CO2 in Dulbecco’s modi¢ed
Eagle’s medium containing 25 mM glucose, 100 U/ml penicillin, 100
Wg/ml streptomycin, and 10% fetal bovine serum (culture medium).
For di¡erentiation, con£uent preadipocytes were cultured for 2 days
in culture medium supplemented with 5 WM insulin, 0.5 mM isobu-
tylmethylxanthine and 0.1 WM dexamethasone, and 2 days in culture
medium with 5 WM insulin. The cells were then grown for an addi-
tional 4^8 days in culture medium after which more than 90% of the
cells had accumulated fat droplets. Adipocytes were maintained for
6 h in serum-free medium before the di¡erent e¡ectors were added for
16 h as described in the ¢gure legends.
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2.3. Analysis of resistin gene expression
Real-time reverse transcription-polymerase chain reaction (RT-
PCR) analyses were performed in a £uorescent temperature cycler
(LightCycler, Roche Molecular Biochemicals, Mannheim, Germany)
according to the manufacturer’s instructions. Brie£y, total RNA was
isolated from 3T3-L1 cells using TRIzol reagent (Life Technologies)
and 1 Wg of total RNA was reverse transcribed using standard re-
agents (Life Technologies). One-tenth (2 Wl) of each RT reaction
served as a template in a 20 Wl PCR containing 3 mM MgCl2, 0.5
WM of each primer and 1ULightCycler DNA Master SYBR Green I
mix (Roche Molecular Biochemicals). After initial denaturation at
94‡C for 30 s, reactions were cycled 40 times using the following
parameters for resistin detection: 95‡C for 1 s, primer annealing at
61‡C for 7 s, and primer extension at 72‡C for 11 s. L-Actin cDNA
was ampli¢ed as follows: 94‡C for 5 s, primer annealing at 60‡C for
7 s, and primer extension at 72‡C for 21 s. SYBR Green I £uorescence
was detected at the end of each cycle to monitor the amount of PCR
product formed during that cycle. At the end of each run, melting
curve pro¢les were produced (cooling the sample to 68‡C and heating
slowly to 95‡C with continuous measurement of £uorescence) to con-
¢rm ampli¢cation of speci¢c transcripts. The following oligonucleo-
tide primers speci¢c for mouse resistin (accession number AF323080)
and L-actin (accession number X03672) were used: resistin, GTACC-
CACGGGATGAAGAACC (sense) and GCAGAGCCACAGGAG-
CAG (antisense); L-actin CCAGGGTGTGATGGTGGGAATG
(sense) and CGCACGATTTCCCTCTCAGCTG (antisense). Cycle-
to-cycle £uorescence emission readings were monitored and quanti¢ed
using the second derivative maximum method of the LightCycler
Software (Roche Molecular Biochemicals). The software determines
the crossing points of individual samples by an algorithm which iden-
ti¢es the ¢rst turning point of the £uorescence curve. This turning
point corresponds to the ¢rst maximum of the second derivative curve
and correlates inversely with the log of the initial template concen-
tration. Relative resistin mRNA levels were normalized to those of L-
actin. The speci¢city of the ampli¢cation product was further veri¢ed
by subjecting the ampli¢cation products to electrophoresis on a 1.5%
agarose gel followed by staining with ethidium bromide.
2.4. Statistical analysis
Results are indicated as mean þ S.E.M. Unpaired Student’s t-tests
were used for analysis of di¡erences between various cell treatments.
P6 0.05 is considered signi¢cant and 6 0.01 highly signi¢cant.
3. Results
3.1. Measurement of resistin mRNA levels in 3T3-L1
adipocytes
To test the reliability of the quantitative real-time RT-PCR
method, increasing amounts of total cellular RNA from dif-
ferentiated 3T3-L1 cells were reverse-transcribed and analyzed
using speci¢c primer pairs for resistin and L-actin (Fig. 1A,B).
Linearity between total RNA used per reaction and amount
of mRNA measured by the LightCycler software was ob-
tained between 1 and 200 ng of total RNA for both mRNA
products (Fig. 1A,B).
3.2. Resistin mRNA levels are decreased by isoproterenol
To identify factors modulating resistin gene expression,
fully di¡erentiated 3T3-L1 cells were treated with isoprotere-
nol, T3, and dexamethasone for 16 h. After isolation of total
RNA resistin mRNA levels normalized to L-actin mRNA
were determined by real-time RT-PCR. Isoproterenol treat-
ment reduced the levels of resistin mRNA dramatically by
about 80% as compared to untreated controls (P6 0.01)
(Fig. 2). In contrast, T3 and dexamethasone did not have a
signi¢cant e¡ect on resistin mRNA levels (Fig. 2).
To determine whether the reduction of resistin mRNA by
isoproterenol is dose-dependent, di¡erentiated 3T3-L1 cells
were incubated with increasing concentrations (0^10 WM) of
this compound. Isoproterenol decreased the level of resistin
mRNA expression to about 20% as compared to non-treated
control cells in a dose-dependent fashion (Fig. 3). At 10 nM
isoproterenol resistin gene expression was reduced by about
50% (P6 0.01) (Fig. 3). Maximum inhibition was observed at
a concentration of 10 WM isoproterenol (Fig. 3).
3.3. Pretreatment of 3T3-L1 adipocytes with propranolol
reverses the inhibitory e¡ect of isoproterenol
Isoproterenol stimulates L-adrenergic receptors. To further
con¢rm that the reduction of resistin mRNA is mediated
through this receptor, 3T3-L1 adipocytes were pretreated
with selective antagonists of the K- and L-adrenergic receptors
(100 WM each) for 1 h before isoproterenol (10 WM) was
added for 16 h. Propranolol, a speci¢c L-adrenergic receptor
antagonist, almost completely reversed the inhibitory e¡ect of
isoproterenol on resistin gene expression (P6 0.01) (Fig. 4). In
contrast, phentolamine, an K-adrenergic receptor antagonist,
rather enhanced the inhibitory e¡ect of isoproterenol on re-
Fig. 1. Measurement of resistin mRNA levels in 3T3-L1 adipocytes.
Increasing amounts of total RNA from fully di¡erentiated 3T3-L1
cells were subjected to quantitative real-time RT-PCR with primers
speci¢c for resistin (A) and L-actin (B) as described in Section 2.
Data are expressed relative to resistin and L-actin mRNA levels
measured with 200 ng RNA ( = 100%). Top panels: agarose gel elec-
trophoresis of the PCR products at cycles 23 (A) and 27 (B).
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sistin mRNA (Fig. 4). These results suggest that the reduction
of resistin gene expression by isoproterenol is mediated via L-
adrenergic receptors.
3.4. The e¡ect of isoproterenol on resistin gene expression can
be mimicked by cholera toxin and forskolin
L-Adrenergic receptors are typically coupled through GS-
proteins to the stimulation of adenylyl cyclase and protein
kinase A. To con¢rm that the inhibitory e¡ect of isoproter-
enol is mediated via a GS-protein pathway, the e¡ects of chol-
era toxin and forskolin on resistin gene expression were ex-
amined. Cholera toxin activates GS-proteins by ADP-
ribosylation, whereas forskolin is a direct activator of adenylyl
cyclase. 3T3-L1 adipocytes were treated with di¡erent concen-
trations of cholera toxin (10, 100, 1000 ng/ml) and forskolin
(2, 20, 200 WM) for 16 h and resistin mRNA levels were
determined by real-time RT-PCR. As shown in Fig. 5, both
e¡ectors signi¢cantly inhibited resistin gene expression in a
dose-dependent manner. At most 90% reduction of resistin
mRNA was observed at concentrations of 1000 ng/ml cholera
toxin and 200 WM forskolin (Fig. 5).
Fig. 2. Resistin gene expression is inhibited by isoproterenol. 3T3-
L1 adipocytes were serum-starved for 6 h before isoproterenol (Iso,
10 WM), T3 (1 WM), or dexamethasone (Dexa, 100 nM) was added
for 16 h. Total RNA was extracted and subjected to quantitative
real-time RT-PCR to determine resistin mRNA levels normalized to
L-actin expression as described in Section 2. Data are expressed rel-
ative to non-treated control (Co) cells ( = 100%). Inset: Agarose gel
electrophoresis of the PCR products at cycles 23 (resistin) and 27
(L-actin). Results are the means þ S.E.M. of four independent ex-
periments. **P6 0.01 comparing isoproterenol-treated with un-
treated control cells.
Fig. 3. Inhibition of resistin gene expression by isoproterenol is
dose-dependent. Fully di¡erentiated 3T3-L1 cells were serum-starved
for 6 h before various concentrations of isoproterenol (Iso) were
added for 16 h. Extraction of total RNA and quantitative real-time
RT-PCR were performed as described in Section 2. Resistin gene
expression normalized to L-actin mRNA levels is expressed relative
to untreated control cells ( = 100%). Results are the means þ S.E.M.
of two independent experiments. *P6 0.05, **P6 0.01 comparing
isoproterenol-treated with non-treated cells.
Fig. 4. Inhibitory e¡ect of isoproterenol on resistin gene expression
is mediated via L-adrenergic receptors. After 5 h serum starvation,
3T3-L1 adipocytes were cultured in the presence or absence of
phentolamine (Phen, 100 WM) or propranolol (Prop, 100 WM) for
1 h before isoproterenol (Iso, 10 WM) was added for 16 h. Total
RNA was extracted and quantitative real-time RT-PCR was per-
formed as described in Section 2. Resistin mRNA levels are normal-
ized to L-actin and expressed relative to non-treated control (Co)
cells ( = 100%). Results are the means þ S.E.M. of four independent
experiments. **P6 0.01 comparing isoproterenol-treated with non-
treated or propranolol-pretreated adipocytes.
Fig. 5. Inhibition of resistin expression by isoproterenol can be
mimicked by cholera toxin and forskolin. 3T3-L1 adipocytes were
serum-starved for 6 h before various concentrations of forskolin
and cholera toxin were added for 16 h as indicated. After extraction
of total RNA, quantitative real-time RT-PCR was performed as de-
scribed in Section 2. Resistin gene expression normalized to L-actin
mRNA levels is expressed relative to untreated control (Co) cells
( = 100%). Results are the means þ S.E.M. of four independent ex-
periments. **P6 0.01 comparing untreated with forskolin- or chol-
era toxin-treated cells.
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4. Discussion
Resistin was recently identi¢ed as an adipocyte-secreted fac-
tor which is overexpressed in obesity and causes insulin resis-
tance [5]. In the present study, we demonstrate for the ¢rst
time that L-adrenergic stimulation decreases resistin gene ex-
pression in 3T3-L1 adipocytes in a dose-dependent fashion.
There is growing evidence that increased activity of the
sympathetic nervous system contributes to insulin resistance
[8]. Our group recently demonstrated that patients with pheo-
chromocytoma are insulin-resistant due to increased serum
levels of catecholamines [9]. In most cases insulin resistance
could be reduced by surgical removal of the tumors [9]. At the
molecular level L-adrenergic stimulation is a strong activator
of lipolysis, which leads to increased serum concentrations of
FFA. FFA have been shown to cause insulin resistance at
least partly by inhibiting insulin signaling [10]. Moreover, se-
rum levels of FFA are already increased before glucose toler-
ance is impaired [11]. Furthermore, we and others have shown
that L-adrenergic activation itself inhibits insulin signaling
molecules such as insulin receptor substrates, which have
been shown to be essential for insulin action [12^14]. How-
ever, in the present study we clearly demonstrate that resistin
mRNA levels are decreased upon isoproterenol treatment.
Thus, it appears likely that L-adrenergic stimulation has a
dual e¡ect on insulin sensitivity. On one hand, activation of
L-adrenergic receptors induces insulin resistance, e.g. by neg-
ative interaction with insulin signaling molecules, on the other
hand, insulin sensitivity might be improved by inhibition of
resistin gene expression. In vivo, insulin resistance-inducing
e¡ects might be more prominent as compared to insulin resis-
tance-reducing pathways. Interestingly, L-adrenoreceptor an-
tagonists, e.g. propranolol, have been shown to impair insulin
sensitivity in vivo [15]. Based on our studies, this e¡ect might
be explained at least partly by increased resistin gene expres-
sion after antagonist treatment. In vivo experiments determin-
ing the e¡ects of various L-adrenergic agonists and antago-
nists on insulin sensitivity and resistin gene expression will
help to better de¢ne the physiological signi¢cance of our in
vitro ¢ndings.
In this study, we present evidence that the inhibitory e¡ect
of isoproterenol on resistin gene expression is mediated via
increased intracellular levels of cAMP. These results are in
accordance with the classical view of L-adrenergic receptors
being coupled to GS-proteins, leading to activation of adenyl-
yl cyclase and protein kinase A [16]. The signaling pathway of
isoproterenol downstream of protein kinase A decreasing re-
sistin mRNA is presently unclear. One possibility is that lipo-
lysis in response to a rise in intracellular cAMP levels may
play a role in the regulation of resistin gene expression. Inter-
estingly, prior in vivo studies have shown that resistin mRNA
expression is inhibited by starvation, a condition accompanied
by increased lipolysis and elevated concentrations of intracel-
lular FFA [5]. Similarly, a reduction of cytosolic FFA induced
by the antilipolytic action of insulin was shown to increase
resistin mRNA levels [7]. Clearly, more work is needed to
elucidate the exact mechanism by which increased cAMP lev-
els lead to reduced resistin gene expression.
Glucocorticoids and thyroid hormones have profound ef-
fects on insulin sensitivity and fat cell metabolism. Thus, it
has been demonstrated that glucocorticoid excess causes insu-
lin resistance [17]. At the molecular level, it has been shown
that dexamethasone treatment decreases expression of glucose
transporter (Glut) 1 and translocation of Glut 4 [18]. In-
creased serum levels of thyroid hormones can also impair
glucose tolerance [19]. This e¡ect might be at least partly
due to impaired expression and translocation of Glut 4 [20].
In our experimental system glucocorticoids and T3 do not
a¡ect resistin gene expression. Therefore, our data do not
support a major role for resistin in insulin resistance caused
by these two hormones. However, in vivo data e.g. of patients
a¡ected by Cushing’s syndrome or Graves’ disease will be
necessary to clearly de¢ne the role of resistin in insulin resis-
tance under conditions of glucocorticoid or thyroid hormone
excess.
In summary, we demonstrate for the ¢rst time that L-ad-
renergic stimulation by isoproterenol reduces the level of re-
sistin mRNA. Furthermore, we show that this inhibitory ef-
fect is mediated via activation of GS-proteins and adenylyl
cyclase. More work will be needed to clarify the signaling
mechanisms linking increased cAMP levels to reduced resistin
expression and to clearly de¢ne the physiological signi¢cance
of the inhibitory e¡ect observed.
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